Beverly, MA, United States of America

Margaret D Scott

USPTO Granted Patents = 4 

Average Co-Inventor Count = 7.0

ph-index = 4

Forward Citations = 102(Granted Patents)


Company Filing History:


Years Active: 2014-2018

Loading Chart...
4 patents (USPTO):

Title: **Innovative Contributions of Margaret D. Scott in Cancer Treatment**

Introduction

Margaret D. Scott is a prominent inventor based in Beverly, MA, known for her significant contributions to cancer research and treatment through her innovative inventions. With a total of four patents to her name, her work focuses primarily on the inhibition of certain mutant forms of human histone methyltransferase EZH2, which plays a crucial role in various cancer processes.

Latest Patents

One of her latest patents, titled "Inhibitors of human EZH2, and methods of use thereof," addresses the inhibition of both wild-type and specific mutant forms of EZH2, the catalytic subunit of the PRC2 complex. This enzyme is responsible for the methylation of lysine 27 on histone H3 (H3-K27). In her invention, the inhibition is particularly selective for mutant forms of EZH2, effectively blocking the trimethylation of H3-K27, which is linked to certain cancers. The developed methods can be utilized to treat common cancers such as follicular lymphoma and diffuse large B-cell lymphoma (DLBCL). Additionally, her patent includes methods for identifying small molecule selective inhibitors of mutant forms of EZH2 and techniques for assessing responsiveness to an EZH2 inhibitor in patients.

Career Highlights

Margaret D. Scott has made remarkable strides in her career, primarily through her role at Epizyme, Inc. Her innovative approaches to cancer treatment and her expertise in molecular biology have established her as a key figure in the field of cancer therapeutics.

Collaborations

Throughout her career, Scott has worked collaboratively with esteemed professionals, including Robert A. Copeland and Victoria M. Richon. These collaborations have propelled research efforts and contributed to advancing the understanding and treatment of cancers associated with EZH2 mutations.

Conclusion

Margaret D. Scott’s contributions to the field of oncology through her patents and research have marked her as an influential inventor. Her pioneering work on EZH2 inhibitors not only showcases her innovative spirit but also holds promise for improving cancer treatment options, ultimately benefiting countless patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…